Research

Research Scholar Grants are one of Vanderbilt’s primary investments to advance faculty research, scholarship and creative expression, while Discovery Grants support new ideas and cutting-edge scholarship that possess high potential for future external support. Read More

A team of Vanderbilt University and Vanderbilt University Medical Center researchers has received a $3.1 million NIH grant to develop advanced patient-specific cochlear implant stimulation models for customized implant programming. Read More

The Vanderbilt Institute for Clinical and Translational Research (VICTR), which provides comprehensive support for clinical and translational research at Vanderbilt University Medical Center (VUMC), has been named Administrative Coordinating Center (ACC) of a national effort to streamline the research response to life-threatening lung and heart problems caused by COVID-19. Read More

People with inoperable anal cancer treated with carboplatin-paclitaxel had fewer complications and lived longer than those who received another chemotherapy that has been more often administered. Read More

Vanderbilt's Data Science Institute researchers are developing a model to use big data to address the impact of COVID-19 on policies, procedures, and resources now and in the future. The tool will help Monroe Carell Jr. Children's Hospital at Vanderbilt evaluate short- and long-term resource needs in order to be fully prepared to meet patients' needs. Read More

Zinc supplementation did not reduce mortality, cardiovascular risk, levels of inflammation or microbial translocation among people with heavy alcohol use living with HIV/AIDS, according to a Vanderbilt-led study. Read More

Vanderbilt University Medical Center is evaluating razuprotafib, a drug used to treat glaucoma, in a new randomized, investigational trial for the prevention and treatment of acute respiratory distress syndrome (ARDS) in adult patients with moderate to severe COVID-19. Read More

The insula, a small region of the brain involved in diverse brain functions had widespread dysconnectivity in schizophrenia, Vanderbilt researchers found. Read More

A single mutation in one gene can impair inhibitory signaling in the brain and cause multiple types of seizures and behavioral abnormalities. Read More

The Outcomes Related to COVID-19 Treated with Hydroxychloroquine among In-patients with Symptomatic Disease (ORCHID) trial stopped enrolling new patients based on the fourth scheduled interim analysis showing no evidence of benefit or harm.  Read More

After discovering a new mechanism for DNA damage repair last year, Vanderbilt biochemists now provide direct evidence for how it works. Read More

Vanderbilt cell biologists have developed an unbiased, quantitative framework for evaluating single-cell data. Read More

On May 27, the All of Us Research Program launched the beta version of its cloud-based research platform, the Researcher Workbench. Read More

The goal of the project—Risk-Aware Market Clearing—is a blueprint for an end-to-end, data-driven approach that balances cost and minimizes system-level risk. Market clearing is the process that keeps the supply level to the demand with no leftover of either. Read More

Vanderbilt University’s Warren Center for Neuroscience Drug Discovery has entered into an exclusive worldwide licensing and collaboration agreement with San Diego-based ACADIA Pharmaceuticals Inc. to develop treatments for disorders like Alzheimer’s and schizophrenia. Read More

Black phosphorus is a crystalline material that is attracting growing research interest from semiconductor device engineers, chemists and material scientists to create high-quality atomically thin films. Read More

Vanderbilt University Medical Center investigators have used high-throughput robotic technology to rapidly study and classify variations in a gene linked to heart rhythm disorders and cardiac conditions. Read More

Vanderbilt University Medical Center scientists have identified a C. diff protein system that senses and captures heme (part of hemoglobin) to build a protective shield that fends off threats from our immune system and antibiotics. Read More

After evaluating the ability of more than 1,500 monoclonal antibodies to bind and neutralize the COVID-19 virus, SARS-CoV-2, in the laboratory, AstraZeneca signed an exclusive license to six candidate antibodies in Vanderbilt’s portfolio. Read More

Staph bacteria may change the factor they use to activate blood clotting — to evade the immune response — a new study suggests. Read More